

Rhythm Biosciences Ltd

15:44 26 Jun 2019

Rhythm Biosciences signs The Alfred Hospital for ColoSTAT clinical test

Rhythm Biosciences Ltd (ASX:RHY) has signed The Alfred Hospital in Melbourne as its third clinical trial site for ColoSTAT®, the lifesaving blood test for the early detection of colorectal cancer.

Associate Professor and Head of Endoscopy at the hospital, Gregor Brown, has been appointed as the site's principal investigator for the trial.

Brown is well recognised for his research into improving colonoscopy techniques including polyp removal during colonoscopy and balloon enteroscopy as well for the development of new treatments for coeliac and inflammatory bowel diseases.

Shares are up more than 6% today to 17.5 cents.

"Deep expertise in colonoscopic research"

Rhythm chief executive officer Glenn Gilbert said: "The Alfred Hospital has a long history of supporting clinical trials and a deep expertise in colonoscopic research.

"Working with The Alfred adds to the credibility of this clinical trial and we look forward to this collaboration and ultimately the results."

Recruitment for the trial is expected to reach around 1,000 patients and will be completed at the end of 2019.

The trial will form a key component for both CE Mark & TGA registration as well as approval to market ColoSTAT in Australia and Europe in 2020.

READ: Rhythm Bioscience welcomes new ColoSTAT trial member in Monash Health

The company continues to work with global parties on the most effective assay development, optimisation and clinical utility of the reagents that will form the core components to the final ColoSTAT test.

Rhythm Bioscience also expects to welcome further hospitals to the ColoSTAT trial in the coming months.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

Price: 0.17

Market Cap: \$17.13 m

1 Year Share Price Graph



Share Information

Code: RHY

Listing: ASX

52 week	High	Low
	0.22	0.13

Sector: Pharma & Biotech

Website: www.rhythmbio.com

Company Synopsis:

Rhythm Biosciences Ltd (ASX:RHY) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.